TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Notice of Investigation of QURE: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Kessler Topaz Meltzer & Check, Llp
Notice of Investigation of QURE: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

uniQure N.V. experienced a significant stock price drop after the FDA raised concerns about the data supporting its gene therapy AMT-130 for Huntington's disease, potentially delaying its Biologics License Application submission.

Insights
AMZN   neutral

Mentioned as a competitive force in cloud services without specific performance details


QURE   negative

Stock price fell over 50% after FDA notification that data for AMT-130 did not provide sufficient evidence to support Biologics License Application, creating uncertainty about future regulatory approval